To the Editor, Oxygenated metabolites of cholesterol belong to a large group called oxysterols [1] . Oxysterols are formed in the human body or ingested in the diet. Despite their low tissue levels, oxysterols play important roles in the organism and, e.g. through interaction with liver X receptors, oxysterol-binding proteins, or drug transporters, can influence both carcinogenesis and cancer progression [2] . The role of cholesterol and oxysterols in breast cancer currently receives increasing attention due to the fact that patients have higher cholesterol levels than healthy controls [3] , and enzymes of biosynthesis of cholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol contribute to endocrine therapy (e.g. tamoxifen or aromatase inhibitors) resistance in breast cancer models in vitro [4] .
Additionally, B-ring oxysterols (e.g. 7-ketocholesterol) are suspected to influence hormonal treatment efficacy via interaction with the antiestrogen binding site and estrogen receptors in tumor cells [5] .
The present study explored the question of feasibility of detection of selected oxysterols (7α-hydroxycholesterol, 7-ketocholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol) in plasma of breast cancer patients. This approach provides basic information about the method suitability, individual variability, and detection limits of oxysterols in circulation of patients before a larger detailed study can be performed. We also asked whether tumor removal causes detectable perturbations in levels of oxysterols that could then be used, e.g. for estimation of the disease risk or monitoring of its recurrence.
A total of 24 histologically diagnosed primary breast carcinoma patients treated in the Oncosurgery Department, Medicon (Prague, Czech Republic), during 2013 were included in the study. Blood samples were collected from each patient 1 day before surgical tumor removal (first sampling) and then from the same patient in the period 12-24 months after surgery (second sampling). As oxysterol levels are affected by circadian and feeding rhythm, patients were asked to refrain from eating after 8:00 PM before the sampling day. Sampling was performed between 8:00 and 9:00 AM on the next day. Blood samples were collected to vacutainer tube with anticoagulant, and plasma was separated immediately after the blood withdrawal. Aliquots were stored at −80 °C.
All patients were informed about the study, and those who agreed and signed an informed consent participated in the study. The study protocol was approved by the Ethical Commission of the National Institute of Public Health in Prague.
The method described by Helmschrodt et al. [6] was adopted for extraction of oxysterols from plasma. Briefly, thawed plasma samples were centrifuged at 3200 × g for 5 min, and 80 μL of plasma was added to vials containing 80 μL of a methanolic solution of a mixture of internal standards (400 pg of the deuterated version of each oxysterol) or blank (methanol without oxysterols). Then 1.44 mL of a methanol/isopropanol (1:1, v/v) mixture was added, and the samples were thoroughly mixed using a vortex device for 1 min and centrifuged for 10 min at 12,500 × g. Supernatants were transferred into amber glass vials and evaporated to dryness at room temperature under a stream of nitrogen in the dark, filled with argon gas, sealed, and stored at −80 °C until analysis. On the day of analysis, extracts were reconstituted with 80 μL of a methanol/water mixture (3:1, v/v) and centrifuged prior to analysis for 5 min at 3220 × g. All solutions contained 0.05% (v/v) butylated hydroxytoluene to prevent autoxidation. Dissolved extracts were subjected to the positive-ion APCI LC/MS/MS analysis as previously described [7] . Briefly, oxysterols were resolved by UPLC (50 °C) on an Acquity BEH octadecylsilane (C18) column (1.7 μm; 1 mm × 100 mm) (Waters) using solvent mixtures of H 2 O/CH 3 OH/CH 3 CN (30:3.5:66.5, v/v/v), holding for 1 min, then programmed to CH 3 OH/CH 3 CN (5:95, v/v) over 4 min with a linear gradient at a flow rate of 0.16 mL/min and quantitated by positive-ion APCI/MS/MS-SRM. The injection volume (onto the column) was 20 μL. Quantitation was done using an isotope ratio method. The limit of quantitation for oxysterols in human plasma was 0.05 ng per sample based on calibration curves for each oxysterol.
Because of the diversion of majority of data from the normal distribution (p < 0.05 by the Shapiro-Wilk test), differences between the compared groups of patients were evaluated by the non-parametric independent Mann-Whitney or Spearman test. The mean levels of oxysterols we analyzed (Figure 1) are comparable with other published data in humans [1] . The 27-hydroxycholesterol level was significantly lower, and the 7-ketocholesterol level was higher in the second sampling compared with the first sampling (p = 0.034 and 0.013, respectively; the Mann-Whitney test). When analyzing individual values, several outliers were noted. Thus, separate analyses without these outliers were performed as well, showing that samples from the second sampling contained significantly higher 7-ketocholesterol levels compared with the corresponding first samplings (p = 0.002; the Mann-Whitney test).
Bearing in mind the potential influence of personal and lifestyle characteristics as age, menopausal status (pre-vs. postmenopausal), body mass index, smoking status (never-smoker vs. current or ex-smoker), or history of steroid homeostasis-related conditions on circulating levels of oxysterols, we addressed the role of these factors All levels in ng/mL of plasma. Outliers and samples below limit of quantification are missing (n = 9/3 for first/second sampling of 25-hydroxycholesterol, n = 0/1 for 7α-hydroxycholesterol, and none for 27-hydroxycholesterol and 7-ketocholesterol). Mean ± SD for first and second sampling is presented for each oxysterol. Statistical significance of differences between the compared groups of patients was evaluated by the Mann-Whitney test.
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in stratified analyses. 7-Ketocholesterol level was significantly higher in the first sampling of patients with premenopausal status compared with postmenopausal patients (p = 0.009) and positively correlated with age (p = 0.019). 7α-Hydroxycholesterol in the first sampling positively correlated with age and body mass index (p = 0.018 and p = 0.004, respectively). 25-Hydroxycholesterol level in the second sampling was significantly higher in neversmokers compared with current or ex-smokers (p = 0.022). Interestingly, the 27-hydroxycholesterol level was significantly higher in the first sampling of patients with positive personal history of steroid homeostasis-related conditions (history of hypercholesterolemia, hypothyroidism, hysterectomy, or hormonal replacement therapy) compared with patients without such conditions. Of note, in the second sampling of these patients, an inverse association was found. Thus, we have not observed consistent trend toward modulation of 7-ketocholesterol levels by lifestyle confounders. However, the history of steroid homeostasisrelated conditions modulating the 27-hydroxycholesterol level in both samplings should be further considered as a potential confounder in future studies.
Patients with tumors expressing estrogen receptor and treated with tamoxifen had significantly higher 7-ketocholesterol levels (p = 0.006) and lower 27-hydroxycholesterol levels (p = 0.020) within the first sampling compared with those without estrogen receptor expression. However, such differences were not observed in analyses of the second sampling. Moreover, patients with tumors expressing estrogen receptor treated with tamoxifen had significantly higher plasma 7-ketocholesterol levels in the second sampling compared with the corresponding first sampling (p = 0.034; the Mann-Whitney test) reflecting the results observed in the whole sample set. The rest of oxysterols did not differ between samplings of this subgroup of patients.
Although human plasma levels of oxysterols have already been assessed by various authors (reviewed, e.g. in [1] ), there is currently only one very recent study reporting differences in levels of various oxysterols in plasma of breast cancer patients detected by high-performance gas chromatography coupled to mass spectrometry (GC-MS). Dalenc et al. [8] compared patients on days 0 and 28 (n = 27) after the beginning of endocrine therapy with tamoxifen or aromatase inhibitors and observed a number of significant changes between both samplings, but none for 7-ketocholesterol and 27-hydroxycholesterol. Hence, we provide the first evidence showing a significant rise of 7-ketocholesterol levels in the plasma of breast cancer patients after surgical removal of tumors irrespective of estrogen receptor expression and ongoing endocrine therapy by tamoxifen. The present study used a different technique for oxysterol level detection, liquid chromato graphy coupled with tandem mass spectrometry (LC-MS/MS), and also differed from the previous study in the fact that we followed breast cancer patients in the early stage I or II of the disease, whereas Dalenc et al. [8] observed significantly higher levels of 25-hydroxycholesterol and 6-oxo-cholestan-3β,5α-diol in metastatic patients compared with adjuvantly treated (i.e. clinically considered as tumor-free) patients. Together with our data, these results indirectly support the view that levels of oxysterols may vary not just as a result of the treatment but can also reflect the presence of tumor cells in the patient's bodies. It remains to be determined whether such variations provide a driving force for the tumor growth and its metastatic spread or are a consequence of tumorigenesis.
In conclusion, the present study shows that the assessment of 7-ketocholesterol, 7α-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol in plasma samples of breast cancer patients is feasible using LC-MS/MS. Most importantly, the above data suggest that 7-ketocholesterol levels rise after tumor removal. Further studies are necessary to assess the reproducibility of this observation and the mechanism behind this phenomenon before clinical utilization, e.g. estimation of disease risk, monitoring of disease recurrence, or employment of therapeutic interventions can be considered.
